Table 1.

Current immunotherapies in phase III clinical trials in GBM

NCT Identifier	Study Title	Condition	Immunotherapy	Status
NCT04277221	ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent GBM	Recurrent glioblastoma	Autologous dendritic cell/tumor antigen	Recruiting
NCT02017717	A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in GBM	Recurrent glioblastoma	Nivolumab ± ipilimumab	Active, not recruiting
NCT03548571	Dendritic Cell Immunotherapy Against Cancer Stem Cells in GBM Patients Receiving Standard Therapy	Newly diagnosed IDH wild-type, MGMT- methylated glioblastoma	Dendritic cell immunization targeting autologous tumor stem cells, survivin, and hTERT	Recruiting
NCT04396860	Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated GBM	Newly diagnosed MGMT-unmethylated glioblastoma	Ipilimumab + nivolumab	Active, not recruiting
NCT02667587	An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With GBM	Newly diagnosed MGMT-methylated glioblastoma	Nivolumab	Active, not recruiting
NCT02617589	An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With GBM	Newly diagnosed MGMT-unmethylated glioblastoma	Nivolumab	Active, not recruiting